Results 211 to 220 of about 19,810 (255)

The Safety and Efficacy of Peptide Receptor Radionuclide Therapy for Gastro-Entero-Pancreatic Neuroendocrine Tumors: A Single Center Experience. [PDF]

Curr Oncol
Piscopo L, Zampella E, Volpe F, Gaudieri V, Nappi C, Di Donna E, Clemente S, Varallo A, Scaglione M, Cuocolo A, Klain M.   +10 more
europepmc   +1 more source

Peptide receptor radionuclide therapy in neuroendocrine tumors

Andrej Doma
openalex   +1 more source

Safety and efficacy of peptide receptor radionuclide therapy in neuroendocrine tumors: A single center experience. [PDF]

PLoS One
Sukrithan V, Armbruster H, Rogers S, Vogt SM, Grenade C, Verschraegen C, Zhou Y, Goyal A, Natwa M, Hussein A, Barr H, Konate D, Batdorf R, Brown A, Williams B, Zhao S, Wei L, Xu M, Shah MH, Konda B.   +19 more
europepmc   +1 more source

Dosimetry in peptide receptor radionuclide therapy

World journal of nuclear medicine, 2013
openaire  

Peptide Receptor Radionuclide Therapy

Journal of Clinical Endocrinology and Metabolism, 2022
Abstract The concept of using a targeting molecule labeled with a diagnostic radionuclide for using positron emission tomography or single photon emission computed tomography imaging with the potential to demonstrate that tumoricidal radiation can be delivered to tumoral sites by administration of the same or a similar targeting molecule
Johannes Hofland, Tessa Brabander, Frederik Verburg   +2 more
exaly   +4 more sources

Peptide Receptor Radionuclide Therapy (PRRT): Innovations and Improvements

Cancers, 2023
Neuroendocrine neoplasms (NENs) are tumors originating from neuroendocrine cells distributed throughout the human body. With an increasing incidence over the past few decades, they represent a highly heterogeneous group of neoplasms, mostly expressing somatostatin receptors (SSTRs) on their cell surface. Peptide receptor radionuclide therapy (PRRT) has
Elettra Merola, Chiara Maria Grana
exaly   +4 more sources

Peptide receptor radionuclide therapy [PDF]

Best Practice and Research in Clinical Endocrinology and Metabolism, 2007
Peptide receptor radionuclide therapy with radiolabelled somatostatin analogues is an emerging and convincing treatment modality for patients with unresectable, somatostatin-receptor-positive neuroendocrine tumours. Using radiolabelled somatostatin analogues for imaging became the gold standard for staging of neuroendocrine tumours.
Eric P Krenning
exaly   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

Advances in Peptide Receptor Radionuclide Therapy

Seminars in Nuclear Medicine, 2016
Peptide receptor radionuclide therapy (PRRT) is a very effective treatment modality for advanced neuroendocrine tumors (NETs), representing a teaching model for truly targeted antitumor therapy. With the growing cumulative evidence of PRRT in various treatment settings, we are witnessing increased perception of this modality as a potent treatment ...
Sabet, Amir, Biersack, Hans-Jürgen, Ezziddin, Samer   +2 more
openaire   +3 more sources

Peptide Receptor Radionuclide Therapy: An Overview

Cancer Biotherapy and Radiopharmaceuticals, 2015
Peptide receptor radionuclide therapy (PRRT) is a site-directed targeted therapeutic strategy that specifically uses radiolabeled peptides as biological targeting vectors designed to deliver cytotoxic levels of radiation dose to cancer cells, which overexpress specific receptors.
Ashutosh, Dash, Sudipta, Chakraborty, Maroor Raghavan Ambikalmajan, Pillai, Furn F Russ, Knapp   +3 more
openaire   +2 more sources